CDXS
$1.47
Codexis, Inc.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe,...
Recent News
Codexis (CDXS) Is Up 30.9% After Returning To Q4 Profitability And Issuing 2026 Revenue Guidance
In March 2026, Codexis reported that Q4 2025 revenue rose to US$38.92 million with net income of US$9.6 million, while full-year revenue reached US$70.39 million alongside a reduced net loss and new 2026 revenue guidance of US$72–76 million. The company also highlighted progress for its ECO Synthesis RNA manufacturing platform, including a new siRNA supply agreement for preclinical cardiovascular work and a major technology transfer deal with Merck that materially boosted results. With...
Codexis Inc (CDXS) Q4 2025 Earnings Call Highlights: Revenue Surge and Strategic Partnerships ...
Codexis Inc (CDXS) reports a robust Q4 2025 with significant revenue growth, strategic CDMO agreements, and a strong cash position, despite ongoing challenges.
Codexis, Inc. Q4 2025 Earnings Call Summary
Moby summary of Codexis, Inc.'s Q4 2025 earnings call
Codexis (CDXS) Q4 2025 Earnings Call Transcript
Alison Moore: Thank you, Georgia, and thanks everyone for joining. At Codexis, Inc., our mission is to generate manufacturing solutions using biocatalytic enzymes. The number of siRNA medicines in development are growing at a rate of 5% to 10% per year, and current production technologies will not be able to keep up with demand.
Codexis Q4 Earnings Call Highlights
Codexis (NASDAQ:CDXS) used its fourth-quarter and full-year 2025 earnings call to highlight progress behind its strategic focus on RNA medicines, with management emphasizing technical milestones for its enzymatic siRNA manufacturing platform, growing commercial engagement, and a stronger liquidity p